U.K. Implant Manufacturing Co. Ltd 4541816 false 2024-04-01 2025-03-31 2025-03-31 The principal activity of the company is manufacturing and sale of ophthalmic goods. Digita Accounts Production Advanced 6.30.9574.0 true false 4541816 2024-04-01 2025-03-31 4541816 2025-03-31 4541816 core:RetainedEarningsAccumulatedLosses 2025-03-31 4541816 core:ShareCapital 2025-03-31 4541816 core:CurrentFinancialInstruments 2025-03-31 4541816 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 4541816 core:FurnitureFittingsToolsEquipment 2025-03-31 4541816 core:LandBuildings 2025-03-31 4541816 core:MotorVehicles 2025-03-31 4541816 core:OtherPropertyPlantEquipment 2025-03-31 4541816 bus:SmallEntities 2024-04-01 2025-03-31 4541816 bus:AuditExemptWithAccountantsReport 2024-04-01 2025-03-31 4541816 bus:AbridgedAccounts 2024-04-01 2025-03-31 4541816 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 4541816 bus:RegisteredOffice 2024-04-01 2025-03-31 4541816 bus:Chairman 2024-04-01 2025-03-31 4541816 bus:CompanySecretaryDirector1 2024-04-01 2025-03-31 4541816 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 4541816 core:FurnitureFittings 2024-04-01 2025-03-31 4541816 core:FurnitureFittingsToolsEquipment 2024-04-01 2025-03-31 4541816 core:LandBuildings 2024-04-01 2025-03-31 4541816 core:MotorVehicles 2024-04-01 2025-03-31 4541816 core:OtherPropertyPlantEquipment 2024-04-01 2025-03-31 4541816 core:PlantMachinery 2024-04-01 2025-03-31 4541816 1 2024-04-01 2025-03-31 4541816 countries:EnglandWales 2024-04-01 2025-03-31 4541816 2024-03-31 4541816 core:FurnitureFittingsToolsEquipment 2024-03-31 4541816 core:LandBuildings 2024-03-31 4541816 core:MotorVehicles 2024-03-31 4541816 core:OtherPropertyPlantEquipment 2024-03-31 4541816 2023-04-01 2024-03-31 4541816 2024-03-31 4541816 core:RetainedEarningsAccumulatedLosses 2024-03-31 4541816 core:ShareCapital 2024-03-31 4541816 core:CurrentFinancialInstruments 2024-03-31 4541816 core:CurrentFinancialInstruments core:WithinOneYear 2024-03-31 4541816 core:FurnitureFittingsToolsEquipment 2024-03-31 4541816 core:LandBuildings 2024-03-31 4541816 core:MotorVehicles 2024-03-31 4541816 core:OtherPropertyPlantEquipment 2024-03-31 iso4217:GBP xbrli:pure

Registration number: 4541816

U.K. Implant Manufacturing Co. Ltd

Annual Report and Unaudited Abridged Financial Statements

for the Year Ended 31 March 2025

 

U.K. Implant Manufacturing Co. Ltd

Contents

Company Information

1

Abridged Balance Sheet

2

Notes to the Unaudited Abridged Financial Statements

3 to 7

 

U.K. Implant Manufacturing Co. Ltd

Company Information

Chairman

J Dave

Director

P Dave

Company secretary

P Dave

Registered office

Unit 20 Apex Business Centre
Boscombe Road
Dunstable
Bedfordshire
LU5 4SB

 

U.K. Implant Manufacturing Co. Ltd

(Registration number: 4541816)
Abridged Balance Sheet as at 31 March 2025

Note

2025
£

2024
£

Fixed assets

 

Tangible assets

4

407,842

418,077

Current assets

 

Stocks

136,128

147,894

Debtors

930,378

667,888

Cash at bank and in hand

 

460,808

393,616

 

1,527,314

1,209,398

Creditors: Amounts falling due within one year

(244,844)

(279,631)

Net current assets

 

1,282,470

929,767

Total assets less current liabilities

 

1,690,312

1,347,844

Provisions for liabilities

(10,716)

(9,689)

Net assets

 

1,679,596

1,338,155

Capital and reserves

 

Called up share capital

5

456,878

456,878

Retained earnings

1,222,718

881,277

Shareholders' funds

 

1,679,596

1,338,155

For the financial year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and FRS 102 ‘The Financial Reporting Standard Applicable in the UK and Republic of Ireland’.

All of the company’s members have consented to the preparation of an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

Approved and authorised by the director on 1 September 2025
 

.........................................
J Dave
Chairman

 

U.K. Implant Manufacturing Co. Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 March 2025

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Unit 20 Apex Business Centre
Boscombe Road
Dunstable
Bedfordshire
LU5 4SB

These financial statements were authorised for issue by the director on 1 September 2025.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Basis of preparation

The abridged financial statements have been prepared under the historical cost convention in accordance with the accounting policies set out below. These abridged financial statements were prepared in accordance with Financial Reporting Standard 102, section 1A - The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.

The company is a qualifying entity for the purposes of FRS 102, being a member of a group where the parent of that group prepares publicly available consolidated financial statements, including this company, which are intended to give a true and fair view of the assets, liabilities, financial position and profit and loss of the group. The company has therefore taken advantage of exemptions from the following disclosure requirements:

• Section 4 “Statement of Financial Position”: Reconciliation of the opening and closing number of shares;
• Section 7 “Statement of Cash Flows”: presentation of a statement of cash flow and related notes and disclosures;
• Section 11 “Basic Financial Instruments” and Section 12 “Other Financial Instrument issues”: Carrying amounts, interest, income/expense and net gains/losses for each category of financial instrument; basis of determining fair values; details of collateral, loan defaults or breaches, details of hedges, hedging fair value changes recognised in profit or loss and in other comprehensive income;
• Section 26 “share based payments”: Share-based payment expense charged to profit or loss, reconciliation of opening and closing number and weighted average exercise price of share options, how the fair value of options granted was measured, measurement and carrying amount of liabilities for cash-settled share-based payments, explanation of modifications to arrangements;
• Section 33 "Related Party Disclosures”: Compensation for key management personnel.

The financial statements of the company are consolidated in the financial statements of Caregroup Sight Solutions Private Ltd, a company incorporated in India. These consolidated financial statements are available from its head office, Block No. 310/C&E, Village Dabhasa, Taluka - Padra, Dist. Vadodara - 391440 Gujarat, India.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

 

U.K. Implant Manufacturing Co. Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 March 2025

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts. The company recognises revenue when the amount of revenue can be reliably measured, it is probable that future economic benefits will flow to the entity, specific criteria have been met for each of the company's activities and legal title has passed.

Government grants

Government grants shall be recognised in profit or loss on a systematic basis over the periods in which the entity recognises as expenses the related costs for which the grants are intended to compensate. A government grant that becomes receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the entity with no future related costs shall be recognised in profit or loss of the period in which it becomes receivable.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rates prevailing on the initial transaction dates. Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Tax

Taxation represents the sum of tax currently payable and deferred tax.

The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting date.

Deferred tax is recognised on all timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Freehold land and buildings

2% straight line

Plant and equipment

25% reducing balance

Fixtures and fittings

25% reducing balance

Motor Vehicles

25% reducing balance

 

U.K. Implant Manufacturing Co. Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 March 2025

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method. The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities. Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

3

Staff numbers

The average number of staff employed by the company (including the director) during the year was 11 (2024 : 9).

 

U.K. Implant Manufacturing Co. Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 March 2025

4

Tangible assets

Land and buildings
£

Fixtures and fittings
£

Motor vehicles
 £

Plant and machinery
£

Total
£

Cost or valuation

At 1 April 2024

432,669

40,287

7,000

185,964

665,920

Additions

-

14,911

-

3,501

18,412

Disposals

-

-

(7,000)

-

(7,000)

At 31 March 2025

432,669

55,198

-

189,465

677,332

Depreciation

At 1 April 2024

81,273

25,467

6,299

134,804

247,843

Charge for the year

8,653

6,138

-

13,155

27,946

Eliminated on disposal

-

-

(6,299)

-

(6,299)

At 31 March 2025

89,926

31,605

-

147,959

269,490

Carrying amount

At 31 March 2025

342,743

23,593

-

41,506

407,842

At 31 March 2024

351,396

14,820

701

51,160

418,077

Included within the net book value of land and buildings above is £342,743 (2024 - £351,396) in respect of freehold land and buildings. the directors had the property independently valued by Registered Valuers, in whose opinion the fair value of the land and building as at 31 March 2024 was £660,000. In the opinion of the directors the fair value of the land and buildings as at 31 March 2025 was not significantly different from this valuation.
 

 

U.K. Implant Manufacturing Co. Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 March 2025

5

Share capital

Allotted, called up and fully paid shares

2025

2024

No.

£

No.

£

Ordinary shares of £1 each

456,878

456,878

456,878

456,878

       

6

Parent and ultimate parent undertaking

The company's immediate parent is CareGroup Sight Solutions Private Ltd., incorporated in India.